TMCnet

Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions

Libre Assist 1 uses generative AI to predict how a food choice may affect a person's glucose levels. 2 It then offers ...
Drug Delivery Business

Abbott unveils new FreeStyle Libre app feature for mealtime decisions

Abbott (NYSE:ABT) today unveiled a new feature within its FreeStyle Libre app for continuous glucose monitoring (CGM).
Fierce Biotech

Abbott launches AI-based Libre Assist, its new in-app feature for meal planning

Abbott is tapping the spirit of new beginnings for the New Year by unveiling a “gamechanger" feature within the company’s ...

Should Abbott’s AI-Powered Libre Assist Shift Its Diabetes Platform Strategy Narrative for ABT Investors?

In early January 2026, Abbott Laboratories unveiled Libre Assist, an AI-powered feature within its Libre app that helps U.S.
MobiHealthNews

With new FDA clearance, Abbott Freestyle Libre users can ditch handheld readers for an app

Just a short while after securing a CE Mark for its second generation device, Abbott has been granted FDA clearance for FreeStyle LibreLink, a companion mobile app for its 10 to 14-day CGM. The launch ...

Abbott's FreeStyle Libre 3 Plus Now Covered Across Canada

Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in ...